Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint to Work With Mass University to Develop Ritalin-Like Compounds

NEW YORK, March 3 (GenomeWeb News) - DNAPrint Genomics will help the Massachusetts College of Pharmacy and Health Sciences develop Ritalin-like compounds, the company said today.

 

The research will be conducted under the supervision of Mark Froimowitz, a researcher at the Boston-based university, who recently licensed Ritalin analogs to DNAPrint. The compounds were developed as possible medications for drug abuse, attention deficit hyperactivity disorder, and depression.

 

DNAPrint will work with Froimowitz to develop theranostic tests based on the compounds, said Hector Gomez, DNAPrint's chairman and chief medical officer.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.